Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to determine whether one 300 mg dose of intravenous
(IV) natalizumab reduces change in infarct volume from Baseline to Day 5 on magnetic
resonance imaging (MRI) in participants with acute ischemic stroke when given at ≤6 hours or
at >6 to ≤9 hours from when they were last known normal (LKN).
The secondary objectives of this study in this study population are as follows: to assess the
efficacy of natalizumab on change in infarct volume from Baseline to Day 30; to assess
efficacy of natalizumab on change in infarct volume from 24 hours to Day 5 and Day 30; to
assess the efficacy of natalizumab on clinical measures of stroke outcome; to assess the
safety of natalizumab in participants with acute ischemic stroke.